Literature DB >> 1533490

Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation.

P Spirito1, E Lakatos, B J Maron.   

Abstract

It has been generally assumed that most patients with hypertrophic cardiomyopathy (HC) who develop atrial fibrillation (AF) have marked left ventricular (LV) hypertrophy and subaortic obstruction. The morphologic and functional features of this subset of patients with HC have not been systematically investigated. The LV morphology and functional profile of 46 patients with HC and chronic AF were compared with those of 81 control patients with HC and normal sinus rhythm. Contrary to expectations, LV hypertrophy (assessed with 2-dimensional echocardiography) was substantially less marked in the patients with AF than in the control patients, and prevalence of subaortic obstruction was similar in the 2 groups. Maximal LV wall thickness and wall thickness index were lower in patients with AF (18 +/- 2 and 56 +/- 7 mm, respectively) than in control patients (22 +/- 6 and 67 +/- 16 mm, respectively; p less than 0.001). Furthermore, mild LV hypertrophy (maximal LV wall thickness less than or equal to 17 mm confined to 1 ventricular segment) was almost twice as frequent in patients with AF (63%) than in control patients (36%; p less than 0.005). Subaortic obstruction was present in 9 patients with AF (20%) and in 28 control patients (35%; p greater than 0.05). In a subgroup of 22 patients with AF who were followed for 4 to 10 years, 5 patients had marked LV wall thinning (greater than or equal to 5 mm, range 5 to 14). In conclusion, these results demonstrate that most patients with HC and chronic AF have the nonobstructive form of HC, and relatively mild LV hypertrophy.

Entities:  

Mesh:

Year:  1992        PMID: 1533490     DOI: 10.1016/0002-9149(92)90939-v

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration.

Authors:  F Cecchi; A Montereggi; I Olivotto; P Marconi; A Dolara; B J Maron
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

Review 2.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 3.  Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy.

Authors:  I Olivotto; B J Maron; F Cecchi
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

4.  Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY).

Authors:  Marion Hourqueig; Guillaume Bouzille; Albert Hagège; Erwan Donal; Mariana Mirabel; Olivier Huttin; Thibaud Damy; Fabien Labombarda; Jean-Christophe Eicher; Philippe Charron; Gilbert Habib; Patricia Réant
Journal:  Clin Res Cardiol       Date:  2021-05-27       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.